Joint Development of Advanced Technology will Improve Clinical Drug Product Compliance
Research Triangle Park, North Carolina, September 27, 2016. Marken announced today that their worldwide depot network was selected by Faubel & Co. Nachf. GmbH as part of a global initiative to develop and implement the use of ‘smart labels’ across the clinical trials supply chain.
As a part of the innovative partnership, Marken will use its depot network to provide the infrastructure needed for Faubel to deliver comprehensive smart label technology for clinical drug product.
Smart Label technology eliminates the physical activities related to re-labeling. The smart label also improves accuracy by directly translating clinical trial protocol, clinical drug product information and patient information to investigators, supply chain providers and patients. As a result, Smart Label technologies will enhance patient safety and make processes such as expiry date extension or protocol pooling more efficient. According to Faubel, the new system takes on special importance with new EU clinical trials guideline ‘Annex VI’ as stability data can be updated on primary labels without opening the secondary packaging.
Frank Jäger, Managing Director of Faubel explains, “We are thrilled to use Marken’s dedicated industry knowledge and global network to aid in the initial development and also act as an early adopter for this exciting new technology. This will facilitate the rollout of our Faubel-Med® Label technology to the clinical trial industry.”
The Marken network of global GMP-compliant depots is specifically designed and strategically located to support the requirements of clinical trials around the world. Marken’s global network combines highly-trained staff within state-of-the-art depots to enhance transportation flexibility and provide logistics expertise. The collaboration with Faubel will begin with Marken’s 1,400 sq m Frankfurt depot which offers a variety of packaging, drug storage and distribution, and temperature options to suit the needs of clients.
“Having been involved since the early days of development of e-labels, I’m excited to see that Marken is incorporating the technology in our global depot network. Using the Faubel-Med® Label and our GMP depots as a global platform enables our clients to make processes like the extension of expiry dates more secure and efficient,” says Sascha Sonnenberg, VP Global CTD Sales & Operations at Marken.
“As innovative technologies enter the market, Marken will continue to be a resource offering a highly specialized GDP network,” said Wes Wheeler, Marken’s Chief Executive Officer. He continued, “Marken is confident that by collaborating with Faubel, we are advancing clinical development which we believe will enhance patient safety.”
Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient services and biological sample shipments, and offers a state of the art GMP-compliant depot network and logistic hubs in 43 locations worldwide. Marken’s 630 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
CONTACT: Christine Noble, firstname.lastname@example.org, +1 919 474 6890, www.marken.com
Faubel is an internationally operating family-owned company in the print, paper and foil-processing industry. Since the beginning, the name Faubel has stood for competence in all aspects of product labeling. Clinical trial labeling has become one of its primary areas of business. The core competence are booklet labels as well as proven structures, transparent communication and innovation to optimizes processes and reduce timelines to the advantage of the pharma industry. The portfolio includes special clinical trial services like label-design, routing as well as overprinting of variable data and codes, checked by 200% camera controls.
CONTACT: Miriam Hüther, +49 5661 7309-219, email@example.comBack to Index